Completed PHASE2 INTERVENTIONAL 2-arm NCT00621218

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

A Pilot Study to Compare Tretinoin Gel, 0.05% to Tretinoin Gel Vehicle When Dosed Once or Twice Daily in Female Subjects With Classical Rosacea

Sponsor: Coria Laboratories, Ltd.

Conditions Rosacea

Interventions tretinoin gel 0.05% vehicle

Updated 6 times since 2017 Last updated: Dec 17, 2008 Started: Feb 29, 2008 Primary completion: Apr 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00621218, this PHASE2 trial focuses on Rosacea and remains completed. Sponsored by Coria Laboratories, Ltd., it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Coria Laboratories, Ltd.

Data source: Coria Laboratories, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Conshohocken, United States